Drug Profile
Bexotegrast - Pliant Therapeutics
Alternative Names: PLN-74809Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Pliant Therapeutics
- Class Anti-inflammatories; Antifibrotics; Butyric acids; Naphthyridines; Quinazolines; Small molecules
- Mechanism of Action Integrin alphavbeta1 inhibitors; Integrin alphaVbeta6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Idiopathic pulmonary fibrosis
- Phase II Primary sclerosing cholangitis
- Preclinical Primary biliary cirrhosis
- Discontinued SARS-CoV-2 acute respiratory disease
Most Recent Events
- 04 Feb 2024 Pliant Therapeutics announces intention to discuss the registration path with regulatory authorities
- 04 Feb 2024 Adverse events data from a phase IIa trial in Primary sclerosing cholangitis released by Pliant Therapeutics
- 08 Jan 2024 Pliant Therapeutics completes a phase IIa INTEGRIS-IPF trial for Idiopathic pulmonary fibrosis (Treatment-experienced) in USA (NCT05621252)